secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2022-02-04T23:59:59+00:00
Accession:  0001804220-22-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q4 revenue surges 104% to $4.95B; REGEN-COV writedown $232M
---------------------------------------------------------------------

- Q4 GAAP diluted EPS $19.69 vs $10.24; non-GAAP EPS $23.72 vs $9.53.
- EYLEA U.S. net sales $1.55B (+15% YoY); full year $5.79B (+17%).
- $232M writedown of REGEN-COV inventory due to Omicron; EUA revised to exclude Omicron regions.
- FY2022 non-GAAP guidance: R&D $2.8B-$3.0B; SG&A $1.65B-$1.77B; gross margin 90-92%.
- Board authorized $3B share repurchase program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422022000004/0001804220-22-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422022000004/regn-20220204.htm
  HTML page:      https://secwatch.observer/filing/0001804220-22-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer